Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS BLOOD ADV
Corrigendum to "Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study" [Eur. J. Cancer 2025 Aug 26;226:115535. PMID: 40743655] Eur J Cancer
Impact of MICA-129 mismatch on HSCT outcomes: Evidence from a large European cohort and meta-analysis TRANSPL CELL THER
METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis Oncogene
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias Leukemia
The impact of cancer survivors' extra risk of non-cancer mortality on net survival estimation Am J Epidemiol
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial Lancet Haematol